Vivos Therapeutics, Inc. (VVOS)
NASDAQ: VVOS · IEX Real-Time Price · USD
2.450
-0.120 (-4.67%)
At close: Jul 19, 2024, 4:00 PM
2.470
+0.020 (0.82%)
Pre-market: Jul 22, 2024, 8:54 AM EDT

Vivos Therapeutics Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Year Ending
TTM Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019 2018
Cash & Equivalents
2.611.643.5224.0318.210.75
Upgrade
Short-Term Investments
00000.080
Upgrade
Cash & Cash Equivalents
2.611.643.5224.0318.290.75
Upgrade
Cash Growth
-62.94%-53.31%-85.36%31.38%2333.51%-41.36%
Upgrade
Receivables
0.530.20.461.721.430.96
Upgrade
Other Current Assets
0.480.621.451.580.670.28
Upgrade
Total Current Assets
3.612.465.4227.3220.391.98
Upgrade
Property, Plant & Equipment
4.634.74.782.830.871.14
Upgrade
Long-Term Investments
00000.810.79
Upgrade
Goodwill and Intangibles
3.253.263.153.182.943.36
Upgrade
Other Long-Term Assets
0.310.310.370.360.310.28
Upgrade
Total Long-Term Assets
8.198.278.36.374.935.57
Upgrade
Total Assets
11.810.7313.7233.6925.337.55
Upgrade
Accounts Payable
2.52.151.410.920.781.08
Upgrade
Deferred Revenue
00002.940
Upgrade
Current Debt
0.480.470.421.270.873.71
Upgrade
Other Current Liabilities
5.094.674.985.323.264.3
Upgrade
Total Current Liabilities
8.077.296.817.517.849.09
Upgrade
Long-Term Debt
1.41.521.9900.420
Upgrade
Other Long-Term Liabilities
1.751.510.110.640.150.08
Upgrade
Total Long-Term Liabilities
3.153.032.110.640.570.08
Upgrade
Total Liabilities
11.2210.328.928.158.419.18
Upgrade
Total Debt
1.8822.411.271.293.71
Upgrade
Debt Growth
-18.70%-17.32%90.75%-1.94%-65.22%440.32%
Upgrade
Retained Earnings
-96.81-93.05-79.47-55.62-35.34-23.28
Upgrade
Shareholders' Equity
0.580.414.825.5416.92-2.94
Upgrade
Net Cash / Debt
0.73-0.351.1122.7717-2.96
Upgrade
Net Cash / Debt Growth
-84.59%--95.14%33.91%--
Upgrade
Net Cash Per Share
0.32-0.291.2026.8033.03-6.00
Upgrade
Working Capital
-4.46-4.83-1.3919.8212.55-7.11
Upgrade
Book Value Per Share
0.250.345.2130.0732.86-5.97
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).